HC Wainwright Has Negative Forecast for ENLV Q2 Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Investment analysts at HC Wainwright reduced their Q2 2026 earnings estimates for shares of Enlivex Therapeutics in a research report issued to clients and investors on Monday, August 3rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.31) per share for the quarter, down from their prior estimate of ($0.30). HC Wainwright currently has a “Buy” rating and a $300.00 target price on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Enlivex Therapeutics’ Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.15) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.03) EPS and FY2027 earnings at ($0.21) EPS.

A number of other analysts have also issued reports on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research report on Friday, June 26th. Zacks Research raised Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Finally, Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 25th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $247.50.

Enlivex Therapeutics Stock Performance

NASDAQ:ENLV opened at $2.11 on Wednesday. Enlivex Therapeutics has a fifty-two week low of $1.80 and a fifty-two week high of $31.50. The company has a 50 day moving average price of $7.71 and a 200 day moving average price of $12.22. The stock has a market capitalization of $35.51 million, a P/E ratio of -0.26 and a beta of 1.60.

Institutional Investors Weigh In On Enlivex Therapeutics

Several large investors have recently added to or reduced their stakes in ENLV. Virtu Financial LLC purchased a new position in Enlivex Therapeutics in the 4th quarter valued at approximately $33,000. Invesco Ltd. purchased a new stake in shares of Enlivex Therapeutics during the fourth quarter worth $43,000. XTX Topco Ltd increased its position in shares of Enlivex Therapeutics by 44.8% during the fourth quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after acquiring an additional 19,132 shares during the period. Jane Street Group LLC raised its stake in shares of Enlivex Therapeutics by 244.1% in the fourth quarter. Jane Street Group LLC now owns 74,082 shares of the company’s stock valued at $52,000 after acquiring an additional 52,553 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of Enlivex Therapeutics in the third quarter valued at $57,000. 1.02% of the stock is owned by hedge funds and other institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.